Clover Health Investments

CLOV

Market cap $1.31B

SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Counterpart Health , Inc. (“Counterpart” or the “Company”), a leading AI-powered physician-enablement platform and subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV), today released key 2025 highlights. The past year was defined by continued publication of research demonstrating the platform's impact on chronic disease management, meaningful product expansion, and the scaled adoption of Counterpart Assistant (CA) by hundreds of live third-party customer clinicians across diverse practice settings.

Clover Health shows strong membership growth, rising revenues and sustained EBITDA gains from Clover Assistant, though near-term margin pressure remains a risk.

WILMINGTON, Del., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, Andrew Toy, will present at the J.P.

Clover Health Investments, Corp. (CLOV) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Clover Health Investments (CLOV) reported earnings 30 days ago. What's next for the stock?

Despite disappointing YTD earnings due to higher than expected medical costs, Clover's expected GAAP profitability in 2026 marks a critical inflection point. Clover's higher returning member mix and targeted growth measures aiming to bring more members under Clover Assistant quicker are major tailwinds to medical costs next year, in my opinion. Clover Assistant's early diagnosis capabilities set the company up to benefit from the CMS' Part D measures aiming to normalize cost pressures on plans, in my opinion.

WILMINGTON, Del., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the 2025 Citi Global Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. Eastern Time.

Clover Health Investments, Corp. ( CLOV ) UBS Global Healthcare Conference 2025 November 11, 2025 11:00 AM EST Company Participants Peter Kuipers - Chief Financial Officer Presentation Unknown Analyst Okay. All right.

Clover Health Investments (CLOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Clover Health's Q3 sales soar 50%, but higher Insurance costs and a raised BER outlook weigh on investor sentiment.